Abstract:Background: Liver cirrhosis is the common end-stage of liver disease which lacks effective treatment, thus studies to determine prevention targets are an urgent need. The intestinal microbiota (IM) play important roles in modulating liver diseases which are mediated by microbial metabolites. Despite decades of growing microbial studies, whether IM contribute to the development of cirrhosis and the intimate metabolic link remain obscure. Here, we aimed to reveal the dynamic alterations of microbial composition and metabolic signatures in carbon tetrachloride (CCl 4 )-induced liver cirrhosis mice. Methods: CCl 4 -treated mice or normal control (NC) were sacrificed ( n = 10 per group) after 5 and 15 weeks of intervention. The disease severity was confirmed by Masson’s trichrome or Sirius red staining. Metagenomics sequencing and fecal untargeted metabolomics were performed to evaluate the composition and metabolic function of IM in parallel with the development of cirrhosis. Results: The CCl 4 -treated mice presented liver fibrosis at 5 weeks and liver cirrhosis at 15 weeks indicated by collagen deposition and pseudo-lobule formation, respectively. Mice with liver cirrhosis showed distinct microbial composition from NC, even in the earlier fibrosis stage. Importantly, both of the liver fibrosis and cirrhosis mice were characterized with the depletion of Deltaproteobacteria ( p < 0.05) and enrichment of Akkermansia ( p < 0.05). Furthermore, fecal metabolomics revealed distinguished metabolomics profiles of mice with liver fibrosis and cirrhosis from the NC. Notably, pathway enrichment analysis pointed to remarkable disturbance of purine ( p < 0.001 at 5 weeks, p = 0.034 at 15 weeks) and pyrimidine metabolic pathways ( p = 0.005 at 5 weeks, p = 0.006 at 15 weeks) during the development of liver cirrhosis. Interestingly, the disorders of pyrimidine and purine metabolites like the known microbial metabolites thymidine and 2′-deoxyuridine had already occurred in liver fibrosis and continued in cirrhosis. Conclusion: These novel findings indicated the crucial role of IM-modulated pyrimidine and purine metabolites in the development of liver cirrhosis, which provides microbial targets for disease prevention.

Gut microbiota of patients with cirrhosis promotes cirrhosis development by injuring intestinal mucosal barrier in mice

Gut Microbiota of Patients with Hepatitis B Virus Related Cirrhosis Promotes Hepatic Fibrosis by Injuring Intestinal Barrier Function in Mice

Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis.

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Intestinal Microbiota and Innate Immunity-Related Gene Alteration in Cirrhotic Rats with Liver Transplantation

Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations with Gastrointestinal Symptoms

Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis

Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses

Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

Alterations of the human gut microbiome in liver cirrhosis

Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China

Comparison of the Gut Microbe Profiles and Numbers Between Patients with Liver Cirrhosis and Healthy Individuals

Cirrhotic complications and intestinal microflora

Therapeutic effect of fecal microbiota transplantation on rats with liver cirrhosis and its influence on gut microbiota

Changes of Intestinal Microbial Community and Serum Inflammato-ry Factors in Cirrhosis Mice

Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis

The fecal microbiota of patients with primary biliary cholangitis (PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC

Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis